# Suzhou Connect Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-connect-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.connectbiopharm.com
- Total disclosed funding: $190M
- Latest round: Series C (Aug 24, 2020)
- Investors on record: 9

## About

Founded in 2012 and based in Taicang, China, Suzhou Connect Biopharmaceuticals, Ltd. operates as a biopharmaceutical company that develops therapies for patients with chronic inflammatory diseases.

## Funding rounds

- Series C, Aug 24, 2020, $115M — HBM Partners, Qiming Venture Partners, Lilly Asia Ventures, RA Capital Management, Boxer Capital
- Series B, Jan 2, 2019, $55M — Qiming Venture Partners, NLVC, Advantech Capital, Co-Win Ventures
- Series A, Jan 24, 2017, $20M — Qiming Venture Partners, NLVC, Co-Win Ventures, Lapam Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A, Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C